Novo Nordisk A S (NYSE: NVO)

Novo Nordisk A/S is a global healthcare company that focuses on the discovery development manufacturing and marketing of pharmaceutical products. The company is a world leader in obesity and diabetes care and also has a rare disease business. Headquartered in Denmark Novo Nordisk employs more than 69 500 people in around 80 countries and markets its products in approximately 170 countries.

Novo Nordisk generates revenue primarily from the sale of its pharmaceutical products. Key product lines include glucagon like peptide 1 receptor agonists for obesity and diabetes such as Ozempic Wegovy Saxenda and Rybelsus modern and human insulins and rare disease therapies covering growth hormone and haemophilia. Sales are made to wholesalers distributors pharmacies hospitals and directly to patients in many markets.

The company operates through two business segments Obesity and Diabetes care and Rare disease.

• Obesity and Diabetes care segment includes the development and sale of glucagon like peptide 1 receptor agonists for obesity and diabetes modern and human insulins and related diabetes care products.

• Rare disease segment focuses on growth hormone therapies and haemophilia products and other treatments for rare endocrine and metabolic disorders.

Novo Nordisk holds a leading position in the global obesity and diabetes markets competing chiefly with Eli Lilly while also facing competition from biosimilar insulin manufacturers and emerging anti obesity drug developers. The company benefits from a broad product portfolio strong manufacturing capacity and a well established research and development pipeline that supports sustained market share.

Novo Nordisk serves patients with diabetes obesity and rare diseases as well as healthcare providers hospitals pharmacies and long term care facilities across the countries where it operates.